All In Biotech

Drug Trial Radar · NCT00477295

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Last checked: Nov 20, 2026Latest source record: Dec 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 583 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

583

Actual

Start

May 2007

Primary completion

Dec 2010

Study completion Jan 2011

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
May 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-arm, randomized, double-blind, non-inferiority study using a flexible dosing regime to allow optimal zonisamide or carbamazepine therapy for individual subjects. Assessment of eligibility will take place at the Screening Visit. The subjects will be randomized to either the carbamazepine or zonisamide arm at the Randomization Visit (T1). T1 must occur as soon as possible (and at least within 14 days) of the Screening Visit in order to optimize subject care.

Conditions

  • Epilepsy

Interventions

  • ZonisamideDrug

    Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.

  • CarbamazepineDrug

    Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced Seizure Freedom for 26-weeks During the Maintenance PhaseTime frame: Week 31 through Week 109

Locations

79 sites in 18 countries. Site status is shown where the registry gives one.

  • Site not named

    Camperdown, Australia

  • Site not named

    Clayton, Australia

  • Site not named

    Fitzroy, Australia

  • Site not named

    Flinders, Australia

  • Site not named

    Heidelberg West, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Queensland, Australia

  • Site not named

    Wellington, Australia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Béthune, France

  • Site not named

    Dijon, France

  • Site not named

    Paris, France

  • Site not named

    Saint-Etienne, France

  • Site not named

    Berlin, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Munich, Germany

  • Site not named

    Schwerin, Germany

  • Site not named

    Westerstede, Germany

  • Site not named

    Athens, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    Budapest, Hungary

  • Site not named

    Debrecen, Hungary

  • Site not named

    Gyula, Hungary

  • Site not named

    Hódmezővásárhely, Hungary

  • Site not named

    Nyregyhaza, Hungary

  • Site not named

    Zalaegerszeg-Pozva, Hungary

  • Site not named

    Bangalore, India

  • Site not named

    Hyderabad, India

  • Site not named

    Koturpuram, India

  • Site not named

    Madurai, India

  • Site not named

    New Delhi, India

  • Site not named

    Pune, India

  • Site not named

    Milan, Italy

  • Site not named

    Monza, Italy

  • Site not named

    Orbassano, Italy

  • Site not named

    Rome, Italy

  • Site not named

    Gdansk, Poland

  • Site not named

    Katowice, Poland

  • Site not named

    Krakow, Poland

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.